Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.


For all participants randomized into the Zio Patch arm of the study; once the patch has been returned, the study team will send a letter to the participant’s GP practice containing information on the presence and duration of any episodes of atrial fibrillation. Participants will also receive a copy of this letter for their information. Clinically significant findings will be reported directly to the GP. The participant’s subsequent management will be at the discretion of their GP, allowing the doctor and participant to discuss their management strategy (including anticoagulation) independently. The study team will not directly initiate treatment or act on the information from the Zio Patch data.

For further information, the 2016 European Society of Cardiology guidelines on the Management of Atrial Fibrillation can be found on the ESC website.

There is also a Clinical Knowledge Summary produced by NICE available on the NICE website.

Download the Patient Information Leaflet and the AMALFI protocol for more information.